These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1426653)

  • 1. A sequential multi-assay protocol for the preclinical assessment of natural product complex carbohydrate immunomodulators.
    Williams DL; Pretus HA; McNamee RB; Jones EL
    Dev Biol Stand; 1992; 77():129-36. PubMed ID: 1426653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan.
    Pretus HA; Ensley HE; McNamee RB; Jones EL; Browder IW; Williams DL
    J Pharmacol Exp Ther; 1991 Apr; 257(1):500-10. PubMed ID: 1902259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NCI preclinical screen of biological response modifiers.
    Talmadge JE; Fidler IJ; Oldham RK
    Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro analysis of immunomodulators.
    Hadden JW
    Dev Biol Stand; 1992; 77():93-5. PubMed ID: 1426676
    [No Abstract]   [Full Text] [Related]  

  • 5. [The immunomodulation of the natural killer activity of the splenocytes in C3HA mice during hepatoma 22a growth].
    Filatova NA; Malygin AM; Goriunova LB; Fel' VIa; Khavinson VKh
    Tsitologiia; 1990; 32(6):652-8. PubMed ID: 2238117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Activation of cellular immunity in mice under normal conditions and in tumor growth during treatment with glucosaminyl muramyl dipeptide].
    Pimenov AA; Rakhmilevich AL; Deev VV; Kirillova IV; Migdal TL; Andronova TM; Fuks BB
    Vopr Med Khim; 1990; 36(1):58-60. PubMed ID: 2343578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
    Talmadge JE; Herberman RB
    Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
    [No Abstract]   [Full Text] [Related]  

  • 8. Ex vivo and in vivo characterization of biological response modifiers (BRMs).
    Masihi KN; Talmadge JE
    Dev Biol Stand; 1992; 77():143-5. PubMed ID: 1426655
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of tumoricidal activity of polymorphonuclear leukocytes by a linear beta-1,3-D-glucan and other immunomodulators in murine cells.
    Morikawa K; Takeda R; Yamazaki M; Mizuno D
    Cancer Res; 1985 Apr; 45(4):1496-501. PubMed ID: 3156669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of the immunomodulators suramin, MER and clenbuterol on the haemopoiesis of mice with virus-induced Rauscher leukemia.
    Zvetkova E; Chowdhury I; Rusev R; Janeva E; Nikolova E; Tzenov I; Trifonov S
    Acta Microbiol Bulg; 1993; 29():47-53. PubMed ID: 8511998
    [No Abstract]   [Full Text] [Related]  

  • 12. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a new peptidyl-hypoxanthine derivative on natural killer cells and antitumor activity.
    Migliorati G; Cornaglia-Ferraris P; Cannarile L; Delfino D; D'Adamio F; Mosci F; Stradi R; Rossi E; Guidi G; Riccardi C
    Cancer Detect Prev; 1991; 15(4):319-22. PubMed ID: 1794138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanism of action of natural lipid immunomodulators].
    Fuks BB; Sterlina AG
    Dokl Akad Nauk SSSR; 1984; 279(5):1261-4. PubMed ID: 6518993
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyporesponsiveness of murine myeloid progenitor cells to glucan following its repeated administration.
    Pospísil M; Vacek A; Hofer M; Viklická S; Pipalová I; Sandula J
    Folia Biol (Praha); 1993; 39(4):178-87. PubMed ID: 8187896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory and antitumoral effects of triterpenoid saponins.
    Plohmann B; Bader G; Hiller K; Franz G
    Pharmazie; 1997 Dec; 52(12):953-7. PubMed ID: 9442560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
    Wiltrout RH; Pilaro AM; Gruys ME; Talmadge JE; Longo DL; Ortaldo JR; Reynolds CW
    J Immunol; 1989 Jul; 143(1):372-8. PubMed ID: 2732472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
    Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
    Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A; Nowicky JW
    Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OK-432 stimulates primary production and activity of murine natural killer cells.
    Pollack SB
    Nat Immun Cell Growth Regul; 1987; 6(5):224-36. PubMed ID: 3444437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.